Investigational Drug Information for Bococizumab
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Bococizumab?
Bococizumab is an investigational drug.
There have been 10 clinical trials for Bococizumab.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2013.
The most common disease conditions in clinical trials are Hyperlipoproteinemias, Hyperlipidemias, and Dyslipidemias. The leading clinical trial sponsors are Pfizer, University of California, San Francisco, and San Francisco General Hospital.
There are seven US patents protecting this investigational drug and eighty-seven international patents.
Summary for Bococizumab
| US Patents | 7 |
| International Patents | 87 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2013-10-01) |
| Vendors | 0 |
Recent Clinical Trials for Bococizumab
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects | Pfizer | Phase 3 |
| Bococizumab HIV Evaluation (B-HIVE) Study | Pfizer | Phase 3 |
| Bococizumab HIV Evaluation (B-HIVE) Study | San Francisco General Hospital | Phase 3 |
Clinical Trial Summary for Bococizumab
Top disease conditions for Bococizumab
Top clinical trial sponsors for Bococizumab
US Patents for Bococizumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Bococizumab | See Plans and Pricing | Peptide-mediated delivery of immunoglobulins across the blood-brain barrier | Mayo Foundation for Medical Education and Research (Rochester, MN) | See Plans and Pricing |
| Bococizumab | See Plans and Pricing | Antigen-binding proteins that activate the leptin receptor | REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY) | See Plans and Pricing |
| Bococizumab | See Plans and Pricing | Cholestosome vesicles for incorporation of molecules into chylomicrons | THERASYN SENSORS, INC. (Eggertsville, NY) | See Plans and Pricing |
| Bococizumab | See Plans and Pricing | Treatment with anti-PCSK9 antibodies | Pfizer Inc. (New York, NY) | See Plans and Pricing |
| Bococizumab | See Plans and Pricing | Binding-triggered transcriptional switches and methods of use thereof | The Regents of the University of California (Oakland, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Bococizumab
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Bococizumab | Argentina | AR106319 | 2035-10-12 | See Plans and Pricing |
| Bococizumab | Argentina | AR115992 | 2035-10-12 | See Plans and Pricing |
| Bococizumab | Australia | AU2016338851 | 2035-10-12 | See Plans and Pricing |
| Bococizumab | Brazil | BR112018007318 | 2035-10-12 | See Plans and Pricing |
| Bococizumab | Canada | CA3000215 | 2035-10-12 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
